EMA Authorised: Eltrombopag Viatris (eltrombopag olamine) — Viatris Limited

View source ↗

Summary

The EMA authorised Viatris' eltrombopag olamine (Eltrombopag Viatris) for immune thrombocytopenia (idiopathic thrombocytopenic purpura), establishing EU marketi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Eltrombopag Viatris (eltrombopag olamine)

Snippet

Status: Authorised. Therapeutic area: Purpura, Thrombocytopenic, Idiopathic. MAH: Viatris Limited. Decision date: 05/02/2026